Neoleukin Therapeutics, Inc. (NLTX) Social Stream



Neoleukin Therapeutics, Inc. (NLTX): $13.96

0.20 (+1.45%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add NLTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#99 of 355

in industry

NEOLEUKIN THERAPEUTICS INC (NLTX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering NLTX.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-11 4 $30 $18 $22.5 $3.44 554.07%
2022-03-01 4 $30 $16 $21.5 $3.44 525%
2022-03-02 4 $25 $16 $20.25 $3.44 488.66%
2022-05-17 4 $25 $6 $17.75 $3.44 415.99%
2022-05-27 4 $22 $6 $13 $3.44 277.91%
2022-06-08 4 $22 $3 $12.25 $3.44 256.1%
2022-07-06 4 $22 $3 $11.8 $3.44 243.02%
2022-08-10 5 $22 $3 $11.8 $3.44 243.02%
2022-08-13 5 $22 $3 $11 $3.44 219.77%
2022-09-17 4 $14 $1 $7.4 $3.44 115.12%
2022-11-15 3 $1 $0.5 $0.75 $3.44 -78.2%
2023-04-05 5 $2 $0.5 $1.166 $3.44 -66.1%
2023-08-07 5 $1.5 $0.5 $1 $3.44 -70.93%
NA 2 $NA $NA $NA $3.44 NA%

The Trend in the Analyst Price Target


Over the past 38 weeks, NLTX's average price target has gone down $1.82.

Over the past 124 days, NLTX's average upside potential has been 42.47%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-04-05 5 2.0 0.5 1.166 0.720 61.94%
2023-05-10 5 1.5 0.5 1.000 0.896 11.61%
2023-08-07 5 1.5 0.5 1.000 0.650 53.85%

NLTX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3.2 0 0 4 0 0 5

The Trend in the Broker Recommendations


NLTX's average broker recommendation rating worsened by 2.2 over the prior 13 months.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NLTX as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, NEOLEUKIN THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 1116.57% of them.
  • In the context of all US stocks, NEOLEUKIN THERAPEUTICS INC's average analyst price target is greater than 199.92% of them.
  • To contextualize these metrics, consider that out of all US stocks, NEOLEUKIN THERAPEUTICS INC's variance in analysts' estimates is lower than -1650.96% of them.
  • To contextualize these metrics, consider that out of Healthcare stocks, NEOLEUKIN THERAPEUTICS INC's number of analysts covering the stock is greater than 466.17% of them.

In the Pharmaceutical Products industry, OCUL, CRBP, and NERV are the three stocks most similar to NEOLEUKIN THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

Is NLTX a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!